{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:41:11Z","timestamp":1793032871922,"version":"4.5.0"},"reference-count":25,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70114141"],"award-info":[{"award-number":["70114141"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>T-cell non-Hodgkin\u2019s lymphomas (T-NHL) are a heterogeneous group of lymphomas with a mature T-cell phenotype. While in some hematological diseases the prognosis improved over the last decades, T-NHL cases often relapse early or present with an initially refractory course. Recently, it has been shown that RNA binding proteins have a crucial role for malignant tumor initiation, progression and treatment response while contributing to chemotherapy resistance. Therefore, we investigated the protein expression of the RNA binding protein X (RBMX), which has been shown to be of great relevance in disease initiation and progression in hematological diseases in 53 T-NHL cases using conventional immunohistochemistry. Low RBMX expression was associated with better response to anthracycline-containing first-line treatment. Furthermore, low RBMX expression predicted an improved overall survival and progression-free survival in univariate analysis. Multivariable Cox regression revealed RBMX as an independent prognostic marker for overall survival (p = 0.007; hazard ratio (HR) = 0.204; 95% confidence interval (CI): 0.064\u20130.646) and progression-free survival (p = 0.006; HR = 0.235; 95% CI: 0.083\u20130.666). The study identifies low RBMX expression to predict better chemotherapy response, overall survival and progression-free survival in patients with T-cell non-Hodgkin\u2019s lymphomas. These results suggest that RBMX protein expression levels might be a contributing factor towards chemotherapy resistance and thus affect prognosis. Hence, RBMX may be a potential therapeutic target and prognostic marker in T-cell lymphomas.<\/jats:p>","DOI":"10.3390\/cancers13194788","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T01:59:47Z","timestamp":1632707987000},"page":"4788","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["RBMX Protein Expression in T-Cell Lymphomas Predicts Chemotherapy Response and Prognosis"],"prefix":"10.3390","volume":"13","author":[{"given":"Franziska Lea","family":"Sch\u00fcmann","sequence":"first","affiliation":[{"name":"Department of Internal Medicine IV, Haematology and Oncology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0657-6831","authenticated-orcid":false,"given":"Marcus","family":"Bauer","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, 06112 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1506-9559","authenticated-orcid":false,"given":"Elisabeth","family":"Gro\u00df","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Haematology and Oncology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Terziev","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Haematology and Oncology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-2586","authenticated-orcid":false,"given":"Andreas","family":"Wienke","sequence":"additional","affiliation":[{"name":"Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, 06112 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wickenhauser","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, 06112 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mascha","family":"Binder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Haematology and Oncology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-9348","authenticated-orcid":false,"given":"Thomas","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Haematology and Oncology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin\u2019s lymphomas: Distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann. Oncol."},{"key":"ref_2","unstructured":"Swerdlow, S.H., and World Health Organization (2017). International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic And Lymphoid Tissues, International Agency for Research on Cancer. [4th ed.]."},{"key":"ref_3","first-page":"v108","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Prac-tice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Gaulard","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International TCLP. International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.3324\/haematol.2019.218305","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: A report from the prospec-tive International T-Cell Project","volume":"104","author":"Bellei","year":"2019","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of Patients with Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_7","first-page":"3644","article-title":"RBMX contributes to hepatocellular carcinoma progression and sorafenib resistance by specifically binding and stabilizing BLACAT1","volume":"10","author":"Song","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1158\/1078-0432.CCR-05-2656","article-title":"Heterogeneous Nuclear Ribonucleoprotein G Shows Tumor Suppressive Effect against Oral Squamous Cell Carcinoma Cells","volume":"12","author":"Shin","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14303","DOI":"10.1074\/jbc.M901026200","article-title":"Heterogeneous nuclear ribonucleoprotein G regulates splice site selection by binding to CC(A\/C)-rich regions in pre-mRNA","volume":"284","author":"Heinrich","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_10","first-page":"123","article-title":"hnRNP Proteins and Splicing Control","volume":"623","author":"Cloutier","year":"2007","journal-title":"Cancer Biol. Nucl. Envel."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.celrep.2012.02.005","article-title":"RBMX: A Regulator for Maintenance and Centromeric Protection of Sister Chromatid Cohesion","volume":"1","author":"Matsunaga","year":"2012","journal-title":"Cell Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1038\/s41418-020-0570-8","article-title":"RBMX is required for activation of ATR on repetitive DNAs to main-tain genome stability","volume":"27","author":"Zheng","year":"2020","journal-title":"Cell Death Differ."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41586-018-0453-z","article-title":"The NORAD lncRNA assembles a topoisomerase complex critical for genome stability","volume":"561","author":"Munschauer","year":"2018","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.oraloncology.2011.07.012","article-title":"Expression and mutation analysis of heterogeneous nu-clear ribonucleoprotein G in human oral cancer","volume":"47","author":"Shin","year":"2011","journal-title":"Oral Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bbrc.2008.05.175","article-title":"hnRNP G elicits tumor-suppressive activity in part by upregulating the expression of Txnip","volume":"372","author":"Shin","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.lungcan.2014.05.020","article-title":"Oligogenic germline mutations identified in early non-smokers lung adenocarcinoma patients","volume":"85","author":"Renieri","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/ijc.25544","article-title":"Expression levels of hnRNP G and hTra2-beta1 correlate with opposite outcomes in endometrial cancer biology","volume":"128","author":"Ouyang","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hirschfeld, M., Ouyang, Y.Q., Jaeger, M., Erbes, T., Orlowska-Volk, M., Zur Hausen, A., and Stickeler, E. (2015). HNRNP G and HTRA2-BETA1 regu-late estrogen receptor alpha expression with potential impact on endometrial cancer. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1088-1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1038\/s41388-021-01666-z","article-title":"RBMX suppresses tumorigenicity and progression of bladder cancer by interacting with the hnRNP A1 protein to regulate PKM alternative splicing","volume":"40","author":"Yan","year":"2021","journal-title":"Oncogene"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2334\/josnusd.18-0485","article-title":"Underexpression of SRSF3 and its target gene RBMX predicts good prognosis in patients with head and neck cancer","volume":"62","author":"Guo","year":"2020","journal-title":"J. Oral Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s43018-021-00220-w","article-title":"Transcriptional control of CBX5 by the RNA-binding pro-teins RBMX and RBMXL1 maintains chromatin state in myeloid leukemia","volume":"2","author":"Prieto","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"84743","DOI":"10.18632\/oncotarget.21262","article-title":"Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E)","volume":"8","author":"Antonello","year":"2017","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tu-mours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/jcp.48.9.876","article-title":"A \u201cquickscore\u201d method for immunohistochemical semiquantitation: Validation for oestro-gen receptor in breast carcinomas","volume":"48","author":"Detre","year":"1995","journal-title":"J. Clin. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncb2426","article-title":"A genome-wide homologous recombination screen identi-fies the RNA-binding protein RBMX as a component of the DNA-damage response","volume":"14","author":"Adamson","year":"2012","journal-title":"Nat. Cell Biol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4788\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:04:43Z","timestamp":1760166283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":25,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["cancers13194788"],"URL":"https:\/\/doi.org\/10.3390\/cancers13194788","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]}}}